While cancer immunotherapies are definitely becoming more de rigeur these days, that doesn’t mean that good old fashioned targeted therapies have been universally abandoned or forgotten, far from it.
Making strategic choices about how to differentiate targeted therapies is never easy
At recent meetings this year, my attention was caught by one target in particular, and despite its chequered history it seems to be making a comeback of sorts thanks to a more focused and tailored approach to therapy.
There is unlikely to be one panacea for everything, but what about going back to basics and matching patients to appropriate therapy based on the underlying biology and what the patiemt’s tumour is telling us? We should have more success doing that theoretically – is that actually the case in practice?
To illustrate this, we have a few examples to share from one particular niche in oncology that readers may find interesting and useful…
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
This week I was fascinated (but not surprised) to learn an interesting snippet from an article in Forbes on Hal Barron and GSK by Matthew Herper. Herper wrote:
“David Schenkein, the chief executive of Agios Pharmaceuticals, worked for Barron at Genentech. He says he’s never worked with anyone who read more of the original scientific literature on a topic before making a decision.”
This should be a given yet… not everyone does that. Dr Scheinkein (whom we interviewed here) is no slouch either, so that’s quite a compliment. By the way, for an alternative take on the R&D update, check out John Carroll’s article on Endpoints.
Revvin’ up our understanding of the immune system
It is, however, good to see some CMOs and CSOs reading extensively in the literature themselves rather than relying on summaries from project teams, although I highly recommend they should because it’s a great way to keep the brain revved up with new developments and also understand the field more intimately.
This is also one reason why we have regular Journal Club posts on BSB – to highlight important new developments that are worthy of attention and explain why they matter.
It is encouraging that quite a few of our subscribers are c-suite execs, including CEOs, CMOs, and CSOs who often send in links to papers they are curious for an independent perspective on.
It’s time for the latest look at some key research that may have practical impacts in numerous ways…
To learn more from our latest thought leader interview and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.